We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




C-Reactive Protein Assessed for Albuminuria Severity

By LabMedica International staff writers
Posted on 21 Feb 2018
Diabetes is a major cause of early morbidity and mortality in the world and is the leading cause of renal failure, non-traumatic amputations and blindness in adults. More...
Chronic hyperglycemia causes irreversible structural and functional changes in cells leading to the development of microvascular and macrovascular complications.

C-reactive protein is one of the most sensitive markers of subclinical inflammation, and its serum concentration is an indicator of intensity of low-grade chronic inflammation of the arterial wall. Measurement of total albuminuria in 24-hour urine is the gold standard for early detection of nephropathy and its prevention and the most sensitive prognostic factor for assessing the risk of developing clinical nephropathy.

Scientists at Cantonal Hospital Zenica (Zenica, Bosnia and Herzegovina) and their colleagues carried out a prospective study included 69 patients with diabetes mellitus type 2 (T2DM), both sexes (24 males, 45 females), aged 30-82 years. They were divided into two groups: 40 patients with T2DM and normoalbuminuria (T2DM-NA); and 29 patients with T2DM and microalbuminuria (T2DM-MA). Patients were hospitalized at the Department of Internal Medicine, Cantonal Hospital Zenica, in the period January-April 2014.

Biochemical analyses were performed for serum creatinine, urea, high sensitive C-reactive protein (hsCRP), and albumin in 24-hour urine samples. Immunonephelometry measurement of hsCRP was performed on the Nephelometer Analyzer BN II. The 24 urinary albumin measurements were performed using immunoturbidimetric method (PETINIA), and the HbA1c was measured by turbidimetric inhibition immunoassay (TINIA) and an analysis was performed using the Siemens’ Dimension Clinical Chemistry System analyzer.

The team reported that the frequency of patients in T2DM-NA and T2DM-MA groups was not significantly different in relation to sex and age. There was significant difference in relation to duration of diabetes. The mean glucose and HbA1c levels were significantly higher in T2DM-NA group comparing to T2DM-MA group. Serum creatinine, urea and hsCRP were significantly higher in T2DM-MA group compared to T2DM-NA group. Urinary albumin showed significantly positive correlation with the hsCRP, urea and creatinine. A one unit (mg/L) increase in hsCRP concentration was associated with 11.5% increase of odds of microalbuminuria.

The authors concluded that significantly higher values of serum hsCRP in patients with type 2 diabetes mellitus and microalbuminuria in comparison to those with normoalbuminuria as well as the correlation of values of inflammatory marker with urinary albumin implicate a low-grade inflammation in the progression of diabetic nephropathy. The study was published on February 1, 2018, in the journal Medicinski Glasnik.

Related Links:
Cantonal Hospital Zenica


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Acute lymphoblastic leukemia in children and young people requires careful relapse risk assessment as treatment expands beyond standard chemotherapy. (Image Credit: Shutterstock)

New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL

Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea

Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more

Pathology

view channel
Image: The automated IHC assay helps identify mesothelioma and distinguish it from other malignancies, including NSCLC. (Image Credit: Shutterstock)

Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis

Mesothelioma is a rare, deadly cancer that forms in the tissue lining many internal organs. Most patients are diagnosed late, with median overall survival reported at 12 to 18 months. Differential diagnosis... Read more

Technology

view channel
Image: Diatech Pharmacogenetics launches Labcycler, a compact PCR thermal cycler. (Photo courtesy of Diatech Pharmacogenetics)

Compact PCR Thermal Cycler Launches for Routine Molecular Laboratory Workflows

Molecular laboratories rely on nucleic acid analysis to detect molecular information accurately and reproducibly across a wide range of applications. Supporting these routine workflows, a newly launched... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.